Selskabsmeddelelse
03.05.2011

NeuroSearch A/S (NEUR) kan i dag meddele, at ét af selskabets associerede
selskaber, Atonomics A/S (18,8%-ejet) har indgået aftale med Beckman Coulter
(NYSE: BEC) vedrørende udvikling af produkter til Atonomics'
Atolyzer®-platform. Atonomics fokuserer på udvikling af produkter, som med høj
præcision kan diagnosticere patienter inden for flere terapeutiske områder,
herunder hjerte-kar-lidelser, prostatakræft og svangerskabs­sundhed. Som noget
unikt vil denne diagnosticering finde sted uafhængigt af centrallaboratorier og
altså tæt på, hvor patienterne har deres dagligdag.

I forbindelse med underskrivelsen af udviklingsaftalen blev Beckman Coulter
medejer af Atonomics. Aftalen indebærer også aktiekonvertering af lån stillet
fra NeuroSearch til Atonomics og kombineret med udvandingen som følge af
Beckman Coulters investering, ender NeuroSearch med en ejerandel på 18,9%.

For yderligere information se vedhæftet meddelelse fra Atonomics.

I forbindelse Beckman Coulters indtræden som medejere udtaler Patrik Dahlen,
adm. direktør i NeuroSearch:

"Vi er glade for og stolte over at have medvirket til udvikling af den unikke
Atolyzer®- lokaldiagnostiske platform i vores associerede selskab Atonomics og
ser denne aftale med Beckman Coulter som en blåstempling af teknologien og det
kommercielle potentiale. Aftalen er også et vigtigt skridt fremad i
NeuroSearchs overordnede strategi for en udnyttelse af værdierne i de
associerede selskaber som en fremtidig finansiel reserve."

Patrik Dahlen
Adm. direktør

Kontaktpersoner:
Patrik Dahlen, adm. direktør, telefon: 4460 8214 eller 2629 7296
René Schneider, EVP & CFO, telefon: 4460 8700 eller 2911 2097


Om NeuroSearch - Virksomhedsprofil
NeuroSearch A/S er et europæisk baseret biofarmaceutisk selskab, noteret på
NASDAQ OMX Copenhagen A/S (NEUR) og med speciale inden for sygdomme i
centralnervesystemet (CNS). Selskabet har en pipeline af CNS-speciallægemidler,
der omfatter Huntexil® (pridopidine), et unikt lægemiddel i fase III til
behandling af Huntingtons sygdom. NeuroSearch opbygger kommercielle kompetencer
med sigte på at markedsføre Huntexil® gennem en egen marketing- og
salgsorganisation.

NeuroSearch har en veletableret lægemiddelforskningsdivision, NsDiscovery, der
besidder unikke kompetencer inden for ionkanaler og CNS-sygdomme. Selskabet har
strategiske forsknings- og udviklingsalliancer med Janssen Pharmaceutica og Eli
Lilly samt en licensaftale med Abbott. Endvidere har NeuroSearch ejerandele i
et antal ikke børsnoterede selskaber i Life Science-industrien.


------------


FOR IMMEDIATE RELEASE

Atonomics A/S
Copenhagen, Denmark
03.05.2011



Atonomics and Beckman Coulter Enter Agreement for Equity Investment

Investment will Aid Atonomics in Development of Near Patient Tests on New
Atolyzer® Platform

Atonomics A/S announced today that it has entered into an agreement with
Beckman Coulter, Inc. (NYSE: BEC) which will enable Atonomics to advance its
development of diagnostic tests on its Atolyzer® system to address several
important clinical markets including cardiology, maternal health and prostate
cancer. As part of the transaction, Beckman Coulter is taking a minority equity
stake in Atonomics. The Atolyzer platform, which is currently under
development, will be a fully integrated immuno-diagnostic system designed to
deliver central laboratory performance in a near-patient setting.

“The Atolyzer device combines small size and portability in a system that is
based on well-established chemistries, reagents, and technologies. We look
forward to assisting Atonomics in moving this technology toward
commercialization,” said Richard Creager, group vice president of Immunoassay
and Molecular Diagnostics at Beckman Coulter.

“We are extremely pleased to enter into this agreement with Beckman Coulter, a
company dedicated to high quality central laboratory testing with a global
leadership position in immunoassays,” said Thomas Warthoe, Atonomics' CEO. “Its
investment recognizes the unique benefits and broad applicability that the
Atolyzer platform will bring to the diagnostics industry. We believe the
Atolyzer system will be an ideal near-patient partner to Beckman Coulter's
fully automated Access® and UniCel Dxl® platforms. Industry collaborations like
this one are an important part of Atonomics' business strategy.”

Atonomics believes the Atolyzer technology will bridge the performance gap
between central laboratory and point-of-care analyzers that can be operated in
critical care settings such as emergency departments.

Atonomics is today owned by majority shareholders Inventages Venture Capital,
Sunstone Capital and NeuroSearch, who continue to support and believe in the
company's strategy and welcome Beckman Coulter as a new strategic investor in
the company.


About Atonomics
Atonomics is an emerging technology company based in Copenhagen, Denmark, that
designs and manufactures the innovative Atolyzer® Platform for near-patient
testing in hospitals, clinics, physician offices and patient monitoring.
Atonomics is pursuing a strategy to partner with leading players in the
industry to bring a new dimension of quality to the POCT market. The Atolyzer®
platform is a platform for immuno-diagnostic and molecular diagnostic testing.
The Atolyzer® is designed for simplicity and ease of use while preserving
performance and safety. The stand-alone device is operated with a single touch
by any health worker and can be positioned in any location throughout the
hospital, clinic or office where large systems cannot operate, representing
true near-patient testing. For more information, visit www.atonomics.com.

About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops,
manufactures and markets products that simplify, automate and innovate complex
biomedical tests. More than 275,000 Beckman Coulter systems operate in
laboratories around the world, supplying critical information for improving
patient health and reducing the cost of care. Recurring revenue, consisting of
consumable supplies (including reagent test kits), service and operating-type
lease payments, represent about 80% of the company's 2010 revenue of $3.7
billion. For more information, visit www.beckmancoulter.com.

Note on Forward-Looking Statements
This press release contains ”forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including the statement by Richard
Creager regarding the development and potential commercialization of the
Atolyzer device. These statements are based on current expectations and
assumptions. Actual results could differ materially from those anticipated by
these forward-looking statements as a result of a number of risks and
uncertainties, some of which may be beyond the control of Atonomics and/or
Beckman Coulter. Factors that might cause such a difference include, but are
not limited to, the risks and uncertainties involved in the development and
integration of new technologies, and should be considered along with and in
conjunction to all other risks detailed in Beckman Coulter's public filings
with the SEC from time to time, including Beckman Coulter's most recently filed
Annual Report on Form 10-K for the year ended December 31, 2010 and its
subsequently-filed SEC reports. The reader is cautioned not to unduly rely on
these forward-looking statements. Each of Atonomics and Beckman Coulter
expressly disclaims any intent or obligation to update or revise publicly these
forward-looking statements except as required by law.


Contacts:

Atonomics
Thomas Warthoe, CEO
Phone: +45 70271330
Email: [email protected]
Web: www.atonomics.com